ALMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALMS is a good buy for a beginner long-term investor with $50,000-$100,000 available. My direct view is buy now: the stock has credible clinical and cash catalysts, insider buying is strong, and Wall Street sentiment is broadly positive despite one valuation-driven downgrade. The current price is still well below the higher analyst targets, so the setup remains attractive for an investor who wants to act now rather than wait for a better entry.
The technical picture is mixed but constructive enough for a long-term buy. Price closed at 21.71, above the previous close of 21.40, showing short-term strength. MACD histogram is -0.205 but negatively contracting, which suggests bearish momentum is fading. RSI_6 at 33.06 is near oversold/neutral territory, not showing exhaustion on the upside yet. Moving averages are converging, which often precedes a trend decision. Price is just above the pivot area (22.466 is the pivot reference, with S1 at 20.865 and R1 at 24.066), so the stock is trading near the middle-lower part of its near-term range. Similar pattern analysis suggests modest upside over the next month. Overall: not a strong breakout chart, but acceptable for accumulation.
["Deep Track Capital bought 6,772,595 shares in Q1 2026, a very strong institutional confidence signal.", "Insiders are buying, with buying activity up 586.17% over the last month.", "Lead asset envudeucitinib showed a 68% PASI 90 response rate in clinical trials.", "New drug application expected in Q4 2026, creating a clear event-driven catalyst.", "Q1 2026 cash and equivalents of $569.5 million should fund operations into Q4 2027.", "Most analysts remain Buy/Overweight/Outperform with several raised price targets up to $55."]
["No AI Stock Picker or SwingMax signal today.", "One analyst downgrade from Buy to Neutral citing valuation.", "Technical momentum is not yet strong, with MACD still below zero.", "High implied volatility suggests the stock may move sharply around news.", "Hedge funds are neutral with no significant quarterly trend."]
Latest quarter reported was Q1 2026. The available financial update is not fully detailed, but the key takeaway is strong balance-sheet support: $569.5 million in cash and equivalents, expected to fund operations into Q4 2027. That is a major positive for a clinical-stage biotech because it reduces near-term financing pressure and supports continued development. The news flow also suggests the company is advancing a lead asset with meaningful clinical progress.
Analyst trend is mostly positive and has improved recently. Chardan raised its target to $40 and kept Buy. Morgan Stanley raised to $39 and kept Overweight. Guggenheim raised to $34 and kept Buy. Wells Fargo raised to $51 and kept Overweight. Oppenheimer raised to $55 and kept Outperform after strong Phase 3 psoriasis data. Raymond James initiated Strong Buy. The only notable negative was H.C. Wainwright downgrading to Neutral from Buy on valuation, though it still maintained a $25 target. Wall Street pros generally see a favorable risk/reward profile driven by envudeucitinib and upcoming readouts, while the main con is competition and valuation concerns.
